What is the current stock price of Precision BioSciences, Inc. (DTIL)?

As of the latest market data, Precision BioSciences, Inc. (DTIL) is trading at $6.67. The stock has seen a gain of 0.91% today.

Does Precision BioSciences, Inc. (DTIL) pay a dividend?

Based on current data, Precision BioSciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Precision BioSciences, Inc.?

The current market capitalization of Precision BioSciences, Inc. (DTIL) is approximately unavailable.

DTIL

Precision BioSciences, Inc.·Healthcare

6.67

0.908%(+0.06)

Market Closed

7.12

6.747%(+0.45)

After Hours

Last Updated: — ET

52W L: $3.5352W H: $8.82

DTIL NEWS

businesswire.com

3d ago

Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the Company will participate in the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. 25th Annual Needham Virtual Healthcare Conference Format: Virtual Corporate presentation Date/Time: Tuesday, April 14, 2026 at 9:30am.

seekingalpha.com

Mar 17

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript

zacks.com

Mar 12

Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates

Precision BioSciences (DTIL) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to a loss of $3.2 per share a year ago.

businesswire.com

Mar 12

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided a business update. “2025 was an exceptional year for Precision BioSciences marked by meaningful clinical and financial progress. We delivered on what we co.

businesswire.com

Mar 11

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent applications relating to the Company's PBGENE-HBV program. The first Notice of Allowance relates to U.S. Patent Application No. 19/347,136, tit.

businesswire.com

Mar 10

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced presentation of new preclinical study data supporting the potential long-term efficacy of PBGENE-DMD. The data presentation took place during a poster session at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2026 curre.

Company Profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Sector

Healthcare

Industry

Biotechnology

Employees

108

IPO Date

2019-03-28

Beta

1.09

Websitewww.precisionbiosciences.com↗